Bone targeted nano-drug and nano-delivery

Abstract

There are currently no targeted delivery systems to satisfactorily treat bone-related disorders. Many clinical drugs consisting of small organic molecules have a short circulation half-life and do not effectively reach the diseased tissue site. This coupled with repeatedly high dose usage that leads to severe side effects. With the advance in nanotechnology, drugs contained within a nano-delivery device or drugs aggregated into nanoparticles (nano-drugs) have shown promises in targeted drug delivery. The ability to design nanoparticles to target bone has attracted many researchers to develop new systems for treating bone related diseases and even repurposing current drug therapies. In this review, we shall summarise the latest progress in this area and present a perspective for future development in the field. We will focus on calcium-based nanoparticle systems that modulate calcium metabolism and consequently, the bone microenvironment to inhibit disease progression (including cancer). We shall also review the bone affinity drug family, bisphosphonates, as both a nano-drug and nano-delivery system for bone targeted therapy. The ability to target and release the drug in a controlled manner at the disease site represents a promising safe therapy to treat bone diseases in the future.

References

[1] Chindamo, G. et al. Bone diseases: current approach and future perspectives in drug delivery systems for bone targeted therapeutics. Nanomaterials 10, 875 (2020).

[2] Gu W, Wu C, Chen J, Xiao Y. Nanotechnology in the targeted drug delivery for bone diseases and bone regeneration. Int. J. Nanomed., 2013, 8: 2305-2317

[3] Rodan GA, Martin TJ. Therapeutic approaches to bone diseases. Science, 2000, 289: 1508-1514

[4] Bartl, R., Frisch, B., Bartl, R. & Frisch, B. Biology of bone. Osteoporosis: Diagnosis, Prevention, Therapy 7–28 (Springer Berlin Heidelberg, 2009).

[5] Acs, G. & Khurana, J. S. in Essentials of Anatomic Pathology 433–462 (Springer, 2002).

[6] Oryan A, Sahvieh S. Effects of bisphosphonates on osteoporosis: focus on zoledronate. Life Sci., 2021, 264: 118681

[7] Li H, Xiao Z, Quarles LD, Li W. Osteoporosis: mechanism, molecular target and current status on drug development. Curr. Med. Chem., 2021, 28: 1489-1507

[8] Sikon, A. & Batur, P. Profile of teriparatide in the management of postmenopausal osteoporosis. in International Journal of Women’s Health 37–44 (International Federation of Gynecology and Obstetrics, 2010).

[9] Quattrocchi E, Kourlas H. Teriparatide: a review. Clin. Ther., 2004, 26: 841-854

[10] Papapoulos S et al. The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study. Osteoporos. Int., 2015, 26: 2773-2783

[11] Morizio P, Burkhart JI, Ozawa S. Denosumab: a unique perspective on adherence and cost-effectiveness compared with oral bisphosphonates in osteoporosis patients. Ann. Pharmacother., 2018, 52: 1031-1041

[12] Fujiwara, S. et al. Systematic review of raloxifene in postmenopausal Japanese women with osteoporosis or low bone mass (osteopenia). Clin. Interv. Aging 9, 1879–1893 (2014).

[13] Krum SA, Brown M. Unraveling estrogen action in osteoporosis. Cell Cycle, 2008, 7: 1348-1352

[14] Abbasi M et al. Strategies toward rheumatoid arthritis therapy; the old and the new. J. Cell. Physiol., 2019, 234: 10018-10031

[15] Conaghan PG, Cook AD, Hamilton JA, Tak PP. Therapeutic options for targeting inflammatory osteoarthritis pain. Nat. Rev. Rheumatol., 2019, 15: 355-363

[16] Weber AE, Bolia IK, Trasolini NA. Biological strategies for osteoarthritis: from early diagnosis to treatment. Int. Orthop., 2021, 45: 335-344

[17] Kuźnik A, Październiok-Holewa A, Jewula P, Kuźnik N. Bisphosphonates—much more than only drugs for bone diseases. Eur. J. Pharmacol., 2020, 866: 172773

[18] Clark-Price, S. Nonsteroidal anti-inflammatory drugs and corticosteroids. in Pain Management in Veterinary Practice 69–84 (Wiley, 2013).

[19] Lazzarini L, Lipsky BA, Mader JT. Antibiotic treatment of osteomyelitis: what have we learned from 30 years of clinical trials? Int. J. Infect. Dis., 2005, 9: 127-138

[20] Fu Q et al. A nanoagent for concurrent therapy of breast cancer bone metastasis and cancer-induced bone pain through SLC7A11 interruption and photodynamic therapy. Chin. Chem. Lett., 2024, 35

[21] Yang, Y., Yang, W., Zhang, R. & Wang, Y. Peripheral mechanism of cancer-induced bone pain. Neurosc. Bull. 40, 815–830 (2023).

[22] Davila D, Antoniou A, Chaudhry MA. Evaluation of osseous metastasis in bone scintigraphy. Semin. Nucl. Med., 2015, 45: 3-15

[23] Yin JJ, Pollock CB, Kelly K. Mechanisms of cancer metastasis to the bone. Cell Res., 2005, 15: 57-62

[24] Zajączkowska, R., Kocot-Kępska, M., Leppert, W. & Wordliczek, J. Bone pain in cancer patients: mechanisms and current treatment. Int. J. Mol. Sci. 20, 6047 (2019).

[25] Falk S, Dickenson AH. Pain and nociception: mechanisms of cancer-induced bone pain. J. Clin. Oncol., 2014, 32: 1647-1654

[26] van den Beuken-van Everdingen MH, Hochstenbach LM, Joosten EA, Tjan-Heijnen VC, Janssen DJ. Update on prevalence of pain in patients with cancer: systematic review and meta-analysis. J. Pain. Symptom Manag., 2016, 51: 1070-1090.e1079

[27] Anderson RL et al. A framework for the development of effective anti-metastatic agents. Nat. Rev. Clin. Oncol., 2019, 16: 185-204

[28] Choi JH, Ro JY. The 2020 WHO classification of tumors of bone: an updated review. Adv. Anat. Pathol., 2021, 28: 119-138

[29] Sbaraglia M, Bellan E, Dei Tos AP. The 2020 WHO classification of soft tissue tumours: news and perspectives. Pathologica, 2021, 113: 70-84

[30] Svensson E, Christiansen CF, Ulrichsen SP, Rørth MR, Sørensen HT. Survival after bone metastasis by primary cancer type: a Danish population-based cohort study. BMJ open, 2017, 7: e016022

[31] Chu G et al. Bone tumor segmentation on bone scans using context information and random forests. Med. Image Comput. Comput. Assist. Interv., 2014, 17: 601-608

[32] Kong P et al. Skeletal-related events and overall survival of patients with bone metastasis from nonsmall cell lung cancer—a retrospective analysis. Medicine, 2017, 96: e9327

[33] Hong S, Youk T, Lee SJ, Kim KM, Vajdic CM. Bone metastasis and skeletal-related events in patients with solid cancer: a Korean nationwide health insurance database study. PLoS One, 2020, 15: e0234927

[34] Schulman KL, Kohles J. Economic burden of metastatic bone disease in the U.S. Cancer, 2007, 109: 2334-2342

[35] Phanphaisarn A et al. Prevalence and survival patterns of patients with bone metastasis from common cancers in Thailand. Asian Pac. J. Cancer Prev., 2016, 17: 4335-4340

[36] Hernandez RK et al. Incidence of bone metastases in patients with solid tumors: analysis of oncology electronic medical records in the United States. BMC Cancer, 2018, 18

[37] Portales F et al. Bone metastases in gastrointestinal cancer. Clin. Exp. Metastasis, 2015, 32: 7-14

[38] Nguyen DX, Bos PD, Massagué J. Metastasis: from dissemination to organ-specific colonization. Nat. Rev. Cancer, 2009, 9: 274-284

[39] Vinay R, KusumDevi V. Potential of targeted drug delivery system for the treatment of bone metastasis. Drug Deliv., 2016, 23: 21-29

[40] Wu Y et al. Calcium-based biomaterials: unveiling features and expanding applications in osteosarcoma treatment. Bioact. Mater., 2024, 32: 385-399

[41] Clapham DE. Calcium signaling. Cell, 2007, 131: 1047-1058

[42] Bagur R, Hajnóczky G. Intracellular Ca²⁺ sensing: its role in calcium homeostasis and signaling. Mol. Cell, 2017, 66: 780-788

[43] Raffaello A, Mammucari C, Gherardi G, Rizzuto R. Calcium at the center of cell signaling: interplay between endoplasmic reticulum, mitochondria, and lysosomes. Trends Biochem Sci., 2016, 41: 1035-1049

[44] Lloyd-Evans E et al. Niemann-Pick disease type C1 is a sphingosine storage disease that causes deregulation of lysosomal calcium. Nat. Med., 2008, 14: 1247-1255

[45] Christensen KA, Myers JT, Swanson JA. pH-dependent regulation of lysosomal calcium in macrophages. J. Cell Sci., 2002, 115: 599-607

[46] Montero M et al. Chromaffin-cell stimulation triggers fast millimolar mitochondrial Ca²⁺ transients that modulate secretion. Nat. Cell Biol., 2000, 2: 57-61

[47] Rizzuto R, Simpson AW, Brini M, Pozzan T. Rapid changes of mitochondrial Ca²⁺ revealed by specifically targeted recombinant aequorin. Nature, 1992, 358: 325-327

[48] Nicholls DG. Mitochondria and calcium signaling. Cell Calcium, 2005, 38: 311-317

[49] Dupont G, Combettes L, Bird GS, Putney JW. Calcium oscillations. Cold Spring Harb. Perspect. Biol., 2011, 3: a004226

[50] Smedler E, Uhlén P. Frequency decoding of calcium oscillations. Biochim. Biophys. Acta, 2014, 1840: 964-969

[51] Boyan B, Schwartz Z. Rapid vitamin D-dependent PKC signaling shares features with estrogen-dependent PKC signaling in cartilage and bone. Steroids, 2004, 69: 591-597

[52] Bolander J et al. Early BMP, Wnt and Ca²⁺/PKC pathway activation predicts the bone forming capacity of periosteal cells in combination with calcium phosphates. Biomaterials, 2016, 86: 106-118

[53] Dvorak MM et al. Physiological changes in extracellular calcium concentration directly control osteoblast function in the absence of calciotropic hormones. Proc. Natl. Acad. Sci. USA, 2004, 101: 5140-5145

[54] Wada T, Nakashima T, Hiroshi N, Penninger JM. RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol. Med., 2006, 12: 17-25

[55] Leser JM et al. Osteoblast-lineage calcium/calmodulin-dependent kinase 2 delta and gamma regulates bone mass and quality. Proc. Natl. Acad. Sci. USA, 2023, 120

[56] Zhu S et al. Calmodulin interacts with Rab3D and modulates osteoclastic bone resorption. Sci. Rep., 2016, 6

[57] Hetz C. The unfolded protein response: controlling cell fate decisions under ER stress and beyond. Nat. Rev. Mol. Cell Biol., 2012, 13: 89-102

[58] Pahl HL, Baeuerle PA. The ER-overload response: activation of NF-κB. Trends Biochem. Sci., 1997, 22: 63-67

[59] Ruggiano A, Foresti O, Carvalho P. ER-associated degradation: protein quality control and beyond. J. Cell Biol., 2014, 204: 868-878

[60] Rao RV, Ellerby HM, Bredesen DE. Coupling endoplasmic reticulum stress to the cell death program. Cell Death Differ., 2004, 11: 372-380

[61] Wescott AP, Kao JPY, Lederer WJ, Boyman L. Voltage-energized calcium-sensitive ATP production by mitochondria. Nat. Metab., 2019, 1: 975-984

[62] Finkel T et al. The ins and outs of mitochondrial calcium. Circ. Res., 2015, 116: 1810-1819

[63] Mbaya E et al. Calcium signalling-dependent mitochondrial dysfunction and bioenergetics regulation in respiratory chain Complex II deficiency. Cell Death Differ., 2010, 17: 1855-1866

[64] Orrenius S, Gogvadze V, Zhivotovsky B. Calcium and mitochondria in the regulation of cell death. Biochem. Biophys. Res. Commun., 2015, 460: 72-81

[65] Mustaly-Kalimi, S. et al. Protein mishandling and impaired lysosomal proteolysis generated through calcium dysregulation in Alzheimer’s disease. Proc. Natl. Acad. Sci. USA 119, e2211999119 (2022).

[66] Kiani L. Calcium dysregulation could underlie lysosomal impairment in AD. Nat. Rev. Neurol., 2023, 19: 65-65

[67] Pihán, P. et al. Control of lysosomal-mediated cell death by the pH-dependent calcium channel RECS1. Sci. Adv. 7, eabe5469 (2021).

[68] Canclini L et al. Calcium triggers the dissociation of myosin-Va from ribosomes in ribonucleoprotein complexes. FEBS Lett., 2020, 594: 2311-2321

[69] Dvorak MM, Riccardi D. Ca²⁺ as an extracellular signal in bone. Cell Calcium, 2004, 35: 249-255

[70] Lorget F et al. High extracellular calcium concentrations directly stimulate osteoclast apoptosis. Biochem. Biophys. Res. Commun., 2000, 268: 899-903

[71] Lee MN et al. Elevated extracellular calcium ions promote proliferation and migration of mesenchymal stem cells via increasing osteopontin expression. Exp. Mol. Med., 2018, 50: 1-16

[72] Goltzman D, Hendy GN. The calcium-sensing receptor in bone—mechanistic and therapeutic insights. Nat. Rev. Endocrinol., 2015, 11: 298-307

[73] Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat. Rev. Cancer, 2002, 2: 584-593

[74] Rucci N, Teti A. Osteomimicry: how the seed grows in the soil. Calcif. Tissue Int., 2018, 102: 131-140

[75] Ren G, Esposito M, Kang Y. Bone metastasis and the metastatic niche. J. Mol. Med., 2015, 93: 1203-1212

[76] Zagzag J, Hu MI, Fisher SB, Perrier ND. Hypercalcemia and cancer: differential diagnosis and treatment. CA Cancer J. Clin., 2018, 68: 377-386

[77] Guise TA, Wysolmerski JJ. Cancer-associated hypercalcemia. N. Engl. J. Med., 2022, 386: 1443-1451

[78] Bentov S, Aflalo ED, Tynyakov J, Glazer L, Sagi A. Calcium phosphate mineralization is widely applied in crustacean mandibles. Sci. Rep., 2016, 6

[79] Broz ME, Cook RF, Whitney DL. Microhardness, toughness, and modulus of Mohs scale minerals. Am. Mineral., 2006, 91: 135-142

[80] Dorozhkin SV, Epple M. Biological and medical significance of calcium phosphates. Angew. Chem. Int. Ed., 2002, 41: 3130-3146

[81] LeGeros RZ. Calcium phosphate-based osteoinductive materials. Chem. Rev., 2008, 108: 4742-4753

[82] Xiao D et al. The role of calcium phosphate surface structure in osteogenesis and the mechanisms involved. Acta Biomater., 2020, 106: 22-33

[83] Ribas RG et al. Current advances in bone tissue engineering concerning ceramic and bioglass scaffolds: a review. Ceram. Int., 2019, 45: 21051-21061

[84] Samavedi S, Whittington AR, Goldstein AS. Calcium phosphate ceramics in bone tissue engineering: a review of properties and their influence on cell behavior. Acta Biomater., 2013, 9: 8037-8045

[85] Gong T et al. Nanomaterials and bone regeneration. Bone Res., 2015, 3

[86] Yi H, Ur Rehman F, Zhao C, Liu B, He N. Recent advances in nano scaffolds for bone repair. Bone Res., 2016, 4: 16050

[87] Alves Cardoso D, Jansen JA, Leeuwenburgh G. S.C. Synthesis and application of nanostructured calcium phosphate ceramics for bone regeneration. J. Biomed. Mater. Res. Part B Appl. Biomater., 2012, 100B: 2316-2326

[88] Dai H, Hosseinpour S, Hua S, Xu C. Advances in porous inorganic nanomaterials for bone regeneration. Nano TransMed, 2022, 1: e9130005

[89] Wang P et al. Bone tissue engineering via nanostructured calcium phosphate biomaterials and stem cells. Bone Res., 2014, 2

[90] Zhao R et al. Healing of osteoporotic bone defects by micro-/nano-structured calcium phosphate bioceramics. Nanoscale, 2019, 11: 2721-2732

[91] Nudelman F et al. The role of collagen in bone apatite formation in the presence of hydroxyapatite nucleation inhibitors. Nat. Mater., 2010, 9: 1004-1009

[92] Fu F, Shang L, Chen Z, Yu Y, Zhao Y. Bioinspired living structural color hydrogels. Sci. Robot., 2018, 3: eaar8580

[93] Fu F et al. Graphene hybrid colloidal crystal arrays with photo-controllable structural colors. Nanoscale, 2019, 11: 10846-10851

[94] Fu F et al. Bio-inspired self-healing structural color hydrogel. Proc. Natl. Acad. Sci. USA, 2017, 114: 5900-5905

[95] Hao X et al. Brasenia-inspired hydrogel with sustained and sequential release of BMP and WNT activators for improved bone regeneration. Chin. Chem. Lett., 2023, 34

[96] Huang K, Huang J, Zhao J, Gu Z, Wu J. Natural lotus root-based scaffolds for bone regeneration. Chin. Chem. Lett., 2022, 33: 1941-1945

[97] Yang Y et al. Gaussian curvature–driven direction of cell fate toward osteogenesis with triply periodic minimal surface scaffolds. Proc. Natl. Acad. Sci. USA, 2022, 119

[98] Do AV, Khorsand B, Geary SM, Salem AK. 3D printing of scaffolds for tissue regeneration applications. Adv. Health Mater., 2015, 4: 1742-1762

[99] Wu T et al. Cell-free and cytokine-free self-assembling peptide hydrogel-polycaprolactone composite scaffolds for segmental bone defects. Biomater. Sci., 2023, 11: 840-853

[100] Hu X et al. Novel 3D printed shape-memory PLLA-TMC/GA-TMC scaffolds for bone tissue engineering with the improved mechanical properties and degradability. Chin. Chem. Lett., 2023, 34

[101] Yuan B et al. A biomimetically hierarchical polyetherketoneketone scaffold for osteoporotic bone repair. Sci. Adv., 2020, 6

[102] Fu H et al. Acid neutralization and immune regulation by calcium-aluminum-layered double hydroxide for osteoporosis reversion. J. Am. Chem. Soc., 2022, 144: 8987-8999

[103] Li X, Shu X, Shi Y, Li H, Pei X. MOFs and bone: application of MOFs in bone tissue engineering and bone diseases. Chin. Chem. Lett., 2023, 34: 107986

[104] Xu C, Kang Y, Dong X, Jiang D, Qi M. Integration exosomes with MOF-modified multifunctional scaffold for accelerating vascularized bone regeneration. Chin. Chem. Lett., 2023, 34: 107528

[105] Xu C et al. Iron-based metal–organic framework as a dual cooperative release system for enhanced vascularization and bone regeneration. Chin. Chem. Lett., 2023, 34

[106] Zhang Q et al. Metal-phenolic networks modified polyurethane as periosteum for bone regeneration. Chin. Chem. Lett., 2022, 33: 1623-1626

[107] Liu X et al. Metal-polyDNA nanoparticles reconstruct osteoporotic microenvironment for enhanced osteoporosis treatment. Sci. Adv., 2023, 9

[108] Liu J et al. Hierarchically porous calcium–silicon nanosphere-enabled co-delivery of microRNA-210 and simvastatin for bone regeneration. J. Mater. Chem. B, 2021, 9: 3573-3583

[109] Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat. Rev. Cancer, 2004, 4: 891-899

[110] Hao G, Xu ZP, Li L. Manipulating extracellular tumour pH: an effective target for cancer therapy. RSC Adv., 2018, 8: 22182-22192

[111] Webb BA, Chimenti M, Jacobson MP, Barber DL. Dysregulated pH: a perfect storm for cancer progression. Nat. Rev. Cancer, 2011, 11: 671-677

[112] Rofstad EK, Mathiesen B, Kindem K, Galappathi K. Acidic extracellular pH promotes experimental metastasis of human melanoma cells in athymic nude mice. Cancer Res., 2006, 66: 6699-6707

[113] El-Kenawi A et al. Acidity promotes tumour progression by altering macrophage phenotype in prostate cancer. Br. J. Cancer, 2019, 121: 556-566

[114] Huber V et al. Cancer acidity: an ultimate frontier of tumor immune escape and a novel target of immunomodulation. Semin. Cancer Biol., 2017, 43: 74-89

[115] Pilon-Thomas S et al. Neutralization of tumor acidity improves antitumor responses to immunotherapy. Cancer Res., 2016, 76: 1381-1390

[116] Corbet C et al. TGFβ2-induced formation of lipid droplets supports acidosis-driven EMT and the metastatic spreading of cancer cells. Nat. Commun., 2020, 11

[117] Wiley SZ et al. GPR68, a proton-sensing GPCR, mediates interaction of cancer-associated fibroblasts and cancer cells. FASEB J., 2018, 32: 1170-1183

[118] Som A et al. Monodispersed calcium carbonate nanoparticles modulate local pH and inhibit tumor growth in vivo. Nanoscale, 2016, 8: 12639-12647

[119] Li Y et al. CaCO3 nanoparticles incorporated with KAE to enable amplified calcium overload cancer therapy. Biomaterials, 2021, 277

[120] Dong Z et al. Synthesis of CaCO3-based nanomedicine for enhanced sonodynamic therapy via amplification of tumor oxidative stress. Chem., 2020, 6: 1391-1407

[121] Yan J et al. Metal-phenolic nanomedicines regulate T-cell antitumor function for sono-metabolic cancer therapy. ACS Nano, 2023, 17: 14667-14677

[122] Zhang M et al. Calcium-overload-mediated tumor therapy by calcium peroxide nanoparticles. Chem., 2019, 5: 2171-2182

[123] Tang Z, Zhao P, Wang H, Liu Y, Bu W. Biomedicine meets Fenton chemistry. Chem. Rev., 2021, 121: 1981-2019

[124] Liu Y, Wang Y, Song S, Zhang H. Cancer therapeutic strategies based on metal ions. Chem. Sci., 2021, 12: 12234-12247

[125] Hu H et al. New anti-cancer explorations based on metal ions. J. Nanobiotechnol., 2022, 20

[126] Liu B et al. One-step integration of tumor microenvironment-responsive calcium and copper peroxides nanocomposite for enhanced chemodynamic/ion-interference therapy. ACS Nano, 2022, 16: 617-630

[127] Sun Q et al. Calcium peroxide-based nanosystem with cancer microenvironment-activated capabilities for imaging guided combination therapy via mitochondrial Ca²⁺ overload and chemotherapy. ACS Appl. Mater. Interfaces, 2021, 13: 44096-44107

[128] He C et al. A solid lipid coated calcium peroxide nanocarrier enables combined cancer chemo/chemodynamic therapy with O₂/H₂O₂ self-sufficiency. Acta Biomater., 2021, 122: 354-364

[129] Liu C et al. An open source and reduce expenditure ROS generation strategy for chemodynamic/photodynamic synergistic therapy. Nat. Commun., 2020, 11

[130] Ohsawa I et al. Hydrogen acts as a therapeutic antioxidant by selectively reducing cytotoxic oxygen radicals. Nat. Med., 2007, 13: 688-694

[131] Wu Y, Yuan M, Song J, Chen X, Yang H. Hydrogen gas from inflammation treatment to cancer therapy. ACS Nano, 2019, 13: 8505-8511

[132] Gong F et al. Nanoscale CaH₂ materials for synergistic hydrogen-immune cancer therapy. Chem, 2022, 8: 268-286

[133] Zhao P et al. Local generation of hydrogen for enhanced photothermal therapy. Nat. Commun., 2018, 9

[134] Wan W-L et al. In situ nanoreactor for photosynthesizing H₂ gas to mitigate oxidative stress in tissue inflammation. J. Am. Chem. Soc., 2017, 139: 12923-12926

[135] Zhang B et al. Polymer dots compartmentalized in liposomes as a photocatalyst for in situ hydrogen therapy. Angew. Chem. Int. Ed., 2019, 58: 2744-2748

[136] Chen S et al. Local H₂ release remodels senescence microenvironment for improved repair of injured bone. Nat. Commun., 2023, 14

[137] Dong C et al. A calcium fluoride nanozyme for ultrasound-amplified and Ca²⁺-overload-enhanced catalytic tumor nanotherapy. Adv. Mater., 2022, 34

[138] Wang Y-C et al. Mineral nanomedicine to enhance the efficacy of adjuvant radiotherapy for treating osteosarcoma. ACS Appl. Mater. Interfaces, 2022, 14: 5586-5597

[139] Misiak M et al. Biofunctionalized upconverting CaF₂:Yb,Tm nanoparticles for Candida albicans detection and imaging. Nano Res., 2017, 10: 3333-3345

[140] Zhao H et al. Nanomessenger-mediated signaling cascade for antitumor immunotherapy. ACS Nano, 2021, 15: 13188-13199

[141] Liu B et al. A tumor-microenvironment-responsive nanocomposite for hydrogen sulfide gas and trimodal-enhanced enzyme dynamic therapy. Adv. Mater., 2021, 33

[142] Wu J et al. Bioinspired tumor calcification enables early detection and elimination of lung cancer. Adv. Funct. Mater., 2021, 31

[143] Zhou Y et al. Tumor calcification as a prognostic factor in cetuximab plus chemotherapy-treated patients with metastatic colorectal cancer. Anti-Cancer Drugs, 2019, 30: 195-200

[144] Lin, P. P. & Patel, S. in Bone Sarcoma (eds Lin, P. P. & Patel, S.) 75-97 (Springer US, 2013).

[145] Min KH et al. pH-controlled gas-generating mineralized nanoparticles: a theranostic agent for ultrasound imaging and therapy of cancers. ACS Nano, 2015, 9: 134-145

[146] Cai J et al. A CaCO3-based nanoplatform with sonodynamic and tumor microenvironment activated for combined in vitro cancer therapy. Transl. Oncol., 2023, 38

[147] Peng JQ et al. Targeted co-delivery of protein and drug to a tumor in vivo by sophisticated RGD-modified lipid-calcium carbonate nanoparticles. J. Control. Release, 2019, 302: 42-53

[148] Zhao P et al. Biomimetic calcium carbonate nanoparticles delivered IL-12 mRNA for targeted glioblastoma sono-immunotherapy by ultrasound-induced necroptosis. J. Nanobiotechnol., 2022, 20

[149] Maraka, S. & Kennel, K. A. Bisphosphonates for the prevention and treatment of osteoporosis. Br. Med. J. 351, h3783 (2015).

[150] Singh T et al. The critical role of bisphosphonates to target bone cancer metastasis: an overview. J. Drug Target., 2015, 23: 1-15

[151] Li X et al. Zoledronic acid-containing nanoparticles with minimum premature release show enhanced activity against extraskeletal tumor. ACS Appl. Mater. Interfaces, 2019, 11: 7311-7319

[152] Lin Y et al. Calcium-bisphosphonate nanoparticle platform as a prolonged nanodrug and bone-targeted delivery system for bone diseases and cancers. ACS Appl. Bio Mater., 2021, 4: 2490-2501

[153] Niu Y-Q et al. Calcium carbonate: controlled synthesis, surface functionalization, and nanostructured materials. Chem. Soc. Rev., 2022, 51: 7883-7943

[154] Liu Y et al. Bone mineral: a trojan horse for bone cancers. Efficient mitochondria targeted delivery and tumor eradication with nano hydroxyapatite containing doxorubicin. Mater. Today Bio, 2022, 14

[155] Wysowski DK, Greene P. Trends in osteoporosis treatment with oral and intravenous bisphosphonates in the United States, 2002–2012. Bone, 2013, 57: 423-428

[156] Russell RGG. Bisphosphonates: the first 40 years. Bone, 2011, 49: 2-19

[157] Mühlbauer R, Russell R, Williams D, Fleisch H. The effects of diphosphonates, polyphosphates, and calcitonin on “immobilisation osteoporosis” in rats. Eur. J. Clin. Investig., 1971, 1: 336-344

[158] Shane E. Evolving data about subtrochanteric fractures and bisphosphonates. N. Engl. J. Med., 2010, 362: 1825-1827

[159] Kim JH et al. Cytoprotective effect of flavonoid‐induced autophagy on bisphosphonate mediated cell death in osteoblast. J. Cell. Biochem., 2018, 119: 5571-5580

[160] Russell RGG. Bisphosphonates: from bench to bedside. Ann. N. Y. Acad. Sci., 2006, 1068: 367-401

[161] Barbosa JS, Almeida Paz FA, Braga SS. Bisphosphonates, old friends of bones and new trends in clinics. J. Med. Chem., 2021, 64: 1260-1282

[162] Farrell KB, Karpeisky A, Thamm DH, Zinnen S. Bisphosphonate conjugation for bone specific drug targeting. Bone Rep., 2018, 9: 47-60

[163] Eastell R et al. Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients. Osteoporos. Int., 2000, 11: 331-337

[164] Reid DM et al. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet, 2009, 373: 1253-1263

[165] Kates SL, Ackert-Bicknell CL. How do bisphosphonates affect fracture healing? Injury, 2016, 47: S65-S68

[166] Nakagawa T et al. Zoledronate inhibits receptor activator of nuclear factor kappa-B ligand-induced osteoclast differentiation via suppression of expression of nuclear factor of activated T-cell c1 and carbonic anhydrase 2. Arch. oral. Biol., 2015, 60: 557-565

[167] Zhong, Y. & Li, S. New progress in improving the delivery methods of bisphosphonates in the treatment of bone tumors. Drug Des. Dev. Ther. 15, 4939–4959 (2021).

[168] Kuchuk I et al. Incidence, consequences and treatment of bone metastases in breast cancer patients—experience from a single cancer centre. J. Bone Oncol., 2013, 2: 137-144

[169] Menshawy A et al. Denosumab versus bisphosphonates in patients with advanced cancers-related bone metastasis: systematic review and meta-analysis of randomized controlled trials. Support. Care Cancer, 2018, 26: 1029-1038

[170] Guenther A et al. The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation. Int. J. cancer, 2010, 126: 239-246

[171] Sewing L, Steinberg F, Schmidt H, Göke R. The bisphosphonate zoledronic acid inhibits the growth of HCT-116 colon carcinoma cells and induces tumor cell apoptosis. Apoptosis, 2008, 13: 782-789

[172] Pickering L, Mansi J. The role of bisphosphonates in breast cancer management. Curr. Med. Res. Opin., 2002, 18: 284-295

[173] Rogers TL, Holen I. Tumour macrophages as potential targets of bisphosphonates. J. Transl. Med., 2011, 9: 1-17

[174] Coxon FP, Thompson K, Rogers MJ. Recent advances in understanding the mechanism of action of bisphosphonates. Curr. Opin. Pharmacol., 2006, 6: 307-312

[175] Van Acker HH, Anguille S, Willemen Y, Smits EL, Van Tendeloo VF. Bisphosphonates for cancer treatment: mechanisms of action and lessons from clinical trials. Pharmacol. Ther., 2016, 158: 24-40

[176] Hughes DP. Strategies for the targeted delivery of therapeutics for osteosarcoma. Expert Opin. Drug Deliv., 2009, 6: 1311-1321

[177] Conry RM, Rodriguez MG, Pressey JG. Zoledronic acid in metastatic osteosarcoma: encouraging progression free survival in four consecutive patients. Clin. Sarcoma Res., 2016, 6: 1-7

[178] Otero JE et al. Osteoclast inhibition impairs chondrosarcoma growth and bone destruction. J. Orthop. Res., 2014, 32: 1562-1571

[179] Odri GA et al. Zoledronic acid as a new adjuvant therapeutic strategy for Ewing’s sarcoma patients. Cancer Res., 2010, 70: 7610-7619

[180] Odri G et al. Zoledronic acid inhibits pulmonary metastasis dissemination in a preclinical model of Ewing’s sarcoma via inhibition of cell migration. BMC cancer, 2014, 14: 1-9

[181] Hendriks LE et al. Effect of bisphosphonates, denosumab, and radioisotopes on bone pain and quality of life in patients with non–small cell lung cancer and bone metastases: a systematic review. J. Thorac. Oncol., 2016, 11: 155-173

[182] Silvestris N et al. Natural history of malignant bone disease in gastric cancer: final results of a multicenter bone metastasis survey. Plos One, 2013, 8: e74402

[183] Saad F et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J. Natl. Cancer Inst., 2004, 96: 879-882

[184] Russell HV et al. A phase I study of zoledronic acid and low‐dose cyclophosphamide in recurrent/refractory neuroblastoma: a new approaches to neuroblastoma therapy (NANT) study. Pediatr. Blood Cancer, 2011, 57: 275-282

[185] Cornelis, F. et al. Bisphosphonate therapy for unresectable symptomatic benign bone tumors: a long-term prospective study of tolerance and efficacy. Bone 58, 11–16 (2014).

[186] McClung M et al. Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am. J. Med., 2013, 126: 13-20

[187] Kennel, K. A. & Drake, M. T. in Mayo Clinic Proceedings Vol. 84, 632–638 (Elsevier, 2009).

[188] Hue TF et al. Effect of bisphosphonate use on risk of postmenopausal breast cancer: results from the randomized clinical trials of alendronate and zoledronic acid. JAMA Intern. Med., 2014, 174: 1550-1557

[189] Kimmel D. Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates. J. Dent. Res., 2007, 86: 1022-1033

[190] Carbone EJ et al. Osteotropic nanoscale drug delivery systems based on small molecule bone-targeting moieties. Nanomed. Nanotechnol. Biol. Med., 2017, 13: 37-47

[191] Gao X et al. Targeting nanoparticles for diagnosis and therapy of bone tumors: opportunities and challenges. Biomaterials, 2021, 265

[192] Clarke B. Normal bone anatomy and physiology. Clin. J. Am. Soc. Nephrol., 2008, 3: S131

[193] Cole LE, Vargo-Gogola T, Roeder RK. Targeted delivery to bone and mineral deposits using bisphosphonate ligands. Adv. Drug Deliv. Rev., 2016, 99: 12-27

[194] Nancollas G et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone, 2006, 38: 617-627

[195] Hochdorffer K, Abu Ajaj K, Schafer-Obodozie C, Kratz F. Development of novel bisphosphonate prodrugs of doxorubicin for targeting bone metastases that are cleaved pH dependently or by cathepsin B: synthesis, cleavage properties, and binding properties to hydroxyapatite as well as bone matrix. J. Med. Chem., 2012, 55: 7502-7515

[196] Cong Y et al. Alendronate-decorated biodegradable polymeric micelles for potential bone-targeted delivery of vancomycin. J. Biomater. Sci., Polym. Ed., 2015, 26: 629-643

[197] Sun W et al. Bone-targeted nanoplatform combining zoledronate and photothermal therapy to treat breast cancer bone metastasis. ACS Nano, 2019, 13: 7556-7567

[198] D’Souza S et al. Engineering of cell membranes with a bisphosphonate-containing polymer using ATRP synthesis for bone targeting. Biomaterials, 2014, 35: 9447-9458

[199] Chaudhari KR et al. Bone metastasis targeting: a novel approach to reach bone using Zoledronate anchored PLGA nanoparticle as carrier system loaded with Docetaxel. J. Control. Release, 2012, 158: 470-478

[200] Wu X et al. Bone-targeting nanoparticle to co-deliver decitabine and arsenic trioxide for effective therapy of myelodysplastic syndrome with low systemic toxicity. J. Control. Release, 2017, 268: 92-101

[201] Yin Q et al. Pamidronate functionalized nanoconjugates for targeted therapy of focal skeletal malignant osteolysis. Proc. Natl. Acad. Sci. USA, 2016, 113: E4601-E4609

[202] Xie H et al. Tracking bisphosphonates through a 20 mm thick porcine tissue by using surface-enhanced spatially offset Raman spectroscopy. Angew. Chem. Int. Ed., 2012, 51: 8509-8511

[203] Xue L et al. Rational design of bisphosphonate lipid-like materials for mRNA delivery to the bone microenvironment. J. Am. Chem. Soc., 2022, 144: 9926-9937

[204] Rotman S et al. Drug delivery systems functionalized with bone mineral seeking agents for bone targeted therapeutics. J. Control. Release, 2018, 269: 88-99

[205] Wang Y et al. Osteotropic peptide-mediated bone targeting for photothermal treatment of bone tumors. Biomaterials, 2017, 114: 97-105

[206] Zhang Y, Wei L, Miron RJ, Shi B, Bian Z. Anabolic bone formation via a site‐specific bone‐targeting delivery system by interfering with semaphorin 4D expression. J. Bone Miner. Res., 2015, 30: 286-296

[207] Ma Z et al. Phage display-derived oligopeptide-functionalized probes for in vivo specific photoacoustic imaging of osteosarcoma. Nanomed. Nanotechnol. Biol. Med., 2017, 13: 111-121

[208] Zayed GM, Tessmar JK. Heterobifunctional poly (ethylene glycol) derivatives for the surface modification of gold nanoparticles toward bone mineral targeting. Macromol. Biosci., 2012, 12: 1124-1136

[209] Miller K et al. Poly (ethylene glycol)–paclitaxel–alendronate self-assembled micelles for the targeted treatment of breast cancer bone metastases. Biomaterials, 2013, 34: 3795-3806

[210] Liu Y et al. Bone-targeting liposome formulation of Salvianic acid A accelerates the healing of delayed fracture Union in Mice. Nanomed. Nanotechnol. Biol. Med., 2018, 14: 2271-2282

[211] Lee D et al. Inhibition of osteoclast differentiation and bone resorption by bisphosphonate-conjugated gold nanoparticles. Sci. Rep., 2016, 6

[212] Au KM et al. Folate-targeted pH-responsive calcium zoledronate nanoscale metal-organic frameworks: turning a bone antiresorptive agent into an anticancer therapeutic. Biomaterials, 2016, 82: 178-193

[213] Zheng L et al. Bone targeting antioxidative nano-iron oxide for treating postmenopausal osteoporosis. Bioact. Mater., 2022, 14: 250-261

[214] Carmona-Sarabia, L. et al. High-affinity extended bisphosphonate-based coordination polymers as promising candidates for bone-targeted drug delivery. ACS Appl. Mater. Interfaces 15, 33397–33412 (2023).

[215] Sun B et al. Bisphosphonate stabilized calcium phosphate nanoparticles for effective delivery of plasmid DNA to macrophages. ACS Appl. Bio. Mater., 2020, 3: 986-996

[216] Sun, B. et al. Mannose-functionalized biodegradable nanoparticles efficiently deliver DNA vaccine and promote anti-tumor immunity. ACS Appl. Mater. Interfaces 13, 14015–14027 (2021).

[217] Chen, J. F., Lin, P. W., Tsai, Y. R., Yang, Y. C. & Kang, H. Y. Androgens and androgen receptor actions on bone health and disease: from androgen deficiency to androgen therapy. Cells 8, 1318 (2019).

[218] Guo Y et al. Remote-controllable bone-targeted delivery of estradiol for the treatment of ovariectomy-induced osteoporosis in rats. J. Nanobiotechnol., 2021, 19: 1-18

[219] Takeuchi I, Fukuda K, Kobayashi S, Makino K. Transdermal delivery of estradiol-loaded PLGA nanoparticles using iontophoresis for treatment of osteoporosis. Biomed. Mater. Eng., 2016, 27: 475-483

[220] Takeuchi I, Kobayashi S, Hida Y, Makino K. Estradiol-loaded PLGA nanoparticles for improving low bone mineral density of cancellous bone caused by osteoporosis: Application of enhanced charged nanoparticles with iontophoresis. Colloids Surf. B Biointerfaces, 2017, 155: 35-40

[221] Hu Y et al. 17β-estradiol-loaded PEGlyated upconversion nanoparticles as a bone-targeted drug nanocarrier. ACS Appl. Mater. Interfaces, 2015, 7: 15803-15811

[222] Gill J, Gorlick R. Advancing therapy for osteosarcoma. Nat. Rev. Clin. Oncol., 2021, 18: 609-624

[223] Truong NP et al. An influenza virus-inspired polymer system for the timed release of siRNA. Nat. Commun., 2013, 4

[224] Gu W et al. Polymer nanocarrier system for endosome escape and timed release of siRNA with complete gene silencing and cell death in cancer cells. Biomacromolecules, 2013, 14: 3386-3389

[225] Prasadam I et al. ERK‐1/2 and p38 in the regulation of hypertrophic changes of normal articular cartilage chondrocytes induced by osteoarthritic subchondral osteoblasts. Arthritis Rheum., 2010, 62: 1349-1360

[226] Zhen G et al. Inhibition of TGF-β signaling in mesenchymal stem cells of subchondral bone attenuates osteoarthritis. Nat. Med., 2013, 19: 704-712

[227] Prasadam I et al. Systematic identification, characterization and target gene analysis of microRNAs involved in osteoarthritis subchondral bone pathogenesis. Calcif. Tissue Int., 2016, 99: 43-55

[228] Gao, Y., Patil, S. & Qian, A. The role of microRNAs in bone metabolism and disease. Int. J. Mol. Sci. 21, 6081 (2020).

[229] Sun X et al. Anti-miRNA oligonucleotide therapy for chondrosarcoma. Mol. Cancer Ther., 2019, 18: 2021-2029

[230] Zhao YP et al. Flexible nano-liposomes-based transdermal hydrogel for targeted delivery of dexamethasone for rheumatoid arthritis therapy. Drug Deliv., 2022, 29: 2269-2282

[231] Zhang M et al. Advanced application of stimuli-responsive drug delivery system for inflammatory arthritis treatment. Mater. Today Bio, 2022, 14

[232] Chen L et al. Biomaterial-induced macrophage polarization for bone regeneration. Chin. Chem. Lett., 2023, 34

[233] Clementi C, Miller K, Mero A, Satchi-Fainaro R, Pasut G. Dendritic poly(ethylene glycol) bearing paclitaxel and alendronate for targeting bone neoplasms. Mol. Pharm., 2011, 8: 1063-1072

[234] Gdowski AS, Ranjan A, Sarker MR, Vishwanatha JK. Bone-targeted cabazitaxel nanoparticles for metastatic prostate cancer skeletal lesions and pain. Nanomedicine, 2017, 12: 2083-2095

[235] Zhang X et al. Codelivery of GRP78 siRNA and docetaxel via RGD-PEG-DSPE/DOPA/CaP nanoparticles for the treatment of castration-resistant prostate cancer. Drug Des. Dev. Ther., 2019, 13: 1357-1372

[236] Hoang B, Ernsting MJ, Murakami M, Undzys E, Li SD. Docetaxel-carboxymethylcellulose nanoparticles display enhanced anti-tumor activity in murine models of castration-resistant prostate cancer. Int. J. Pharm., 2014, 471: 224-233

[237] Hoang B et al. Cabazitaxel-conjugated nanoparticles for docetaxel-resistant and bone metastatic prostate cancer. Cancer Lett., 2017, 410: 169-179

[238] Barbanente A et al. Platinum-loaded, selenium-doped hydroxyapatite nanoparticles selectively reduce proliferation of prostate and breast cancer cells co-cultured in the presence of stem cells. J. Mater. Chem. B, 2020, 8: 2792-2804

[239] Evans JC et al. Formulation and evaluation of anisamide-targeted amphiphilic cyclodextrin nanoparticles to promote therapeutic gene silencing in a 3D prostate cancer bone metastases model. Mol. Pharm., 2017, 14: 42-52

[240] Lu, Y. et al. Peptide T7-modified polypeptide with disulfide bonds for targeted delivery of plasmid DNA for gene therapy of prostate cancer. Int. J. Nanomed. 13, 6913–6927 (2018).

[241] Gu Y et al. Study on the cellular internalization mechanisms and in vivo anti-bone metastasis prostate cancer efficiency of the peptide T7-modified polypeptide nanoparticles. Drug Deliv., 2020, 27: 161-169

[242] Katsumi H, Yamashita S, Morishita M, Yamamoto A. Bone-targeted drug delivery systems and strategies for treatment of bone metastasis. Chem. Pharm. Bull., 2020, 68: 560-566

[243] Hao Z et al. Efficient delivery of micro RNA to bone-metastatic prostate tumors by using aptamer-conjugated atelocollagen in vitro and in vivo. Drug Deliv., 2016, 23: 874-881

[244] Satcher RL, Zhang XHF. Evolving cancer-niche interactions and therapeutic targets during bone metastasis. Nat. Rev. Cancer, 2022, 22: 85-101

[245] Kreps, L. M. & Addison, C. L. Targeting intercellular communication in the bone microenvironment to prevent disseminated tumor cell escape from dormancy and bone metastatic tumor growth. Int. J. Mol. Sci. 22, 2911 (2021).

[246] Li C et al. Self-assembly of CXCR4 antagonist peptide–docetaxel conjugates for breast tumor multi-organ metastasis inhibition. Acta Pharm. Sin. B, 2023, 13: 3849-3861

[247] Ross MH et al. Bone-induced expression of integrin β3 enables targeted nanotherapy of breast cancer metastases. Cancer Res., 2017, 77: 6299-6312

[248] Fox GC et al. Targeted therapy to β3 integrin reduces chemoresistance in breast cancer bone metastases. Mol. Cancer Ther., 2021, 20: 1183-1198

[249] Liu C et al. The osteogenic niche-targeted arsenic nanoparticles prevent colonization of disseminated breast tumor cells in the bone. Acta Pharm. Sin. B, 2022, 12: 364-377

[250] Bai SB et al. Bone-targeted PAMAM nanoparticle to treat bone metastases of lung cancer. Nanomedicine, 2020, 15: 833-849

[251] Bai SB et al. Osteoclasts and tumor cells dual targeting nanoparticle to treat bone metastases of lung cancer. Nanomedicine, 2019, 21

[252] Lyu, H., Xiao, Y., Guo, Q., Huang, Y. & Luo, X. The role of bone-derived exosomes in regulating skeletal metabolism and extraosseous diseases. Front. Cell Dev. Biol. 8, 89 (2020).

[253] Samal S, Dash P, Dash M. Drug delivery to the bone microenvironment mediated by exosomes: an axiom or enigma. Int. J. Nanomed., 2021, 16: 3509-3540

[254] Wang J et al. Bone-targeted exosomes: strategies and applications. Adv. Health Mater., 2023, 12

[255] Xie Y et al. Bone-targeted delivery of simvastatin-loaded PEG-PLGA micelles conjugated with tetracycline for osteoporosis treatment. Drug Deliv. Transl. Res., 2018, 8: 1090-1102

[256] Wang Y et al. Fracture-targeted delivery of β-catenin agonists via peptide-functionalized nanoparticles augments fracture healing. ACS Nano, 2017, 11: 9445-9458

[257] Chen SH et al. Alendronate/folic acid-decorated polymeric nanoparticles for hierarchically targetable chemotherapy against bone metastatic breast cancer. J. Mater. Chem. B, 2020, 8: 3789-3800

[258] Sun W, Han Y, Li Z, Ge K, Zhang J. Bone-targeted mesoporous silica nanocarrier anchored by zoledronate for cancer bone metastasis. Langmuir, 2016, 32: 9237-9244

[259] Qiao H et al. Targeting osteocytes to attenuate early breast cancer bone metastasis by theranostic upconversion nanoparticles with responsive plumbagin release. ACS Nano, 2017, 11: 7259-7273

[260] Li, C. et al. Engineered multifunctional nanomedicine for simultaneous stereotactic chemotherapy and inhibited osteolysis in an orthotopic model of bone metastasis. Adv. Mater. 29, 1605754 (2017).

[261] Wang Y et al. Multifunctional melanin-like nanoparticles for bone-targeted chemo-photothermal therapy of malignant bone tumors and osteolysis. Biomaterials, 2018, 183: 10-19

[262] Wang M et al. A targeted and pH-responsive bortezomib nanomedicine in the treatment of metastatic bone tumors. ACS Appl. Mater. Interfaces, 2018, 10: 41003-41011

[263] Chen J et al. Light-responsive micelles loaded with doxorubicin for osteosarcoma suppression. Front. Pharm., 2021, 12

[264] Shi M et al. Copper-doped mesoporous silica nanospheres, a promising immunomodulatory agent for inducing osteogenesis. Acta Biomater., 2016, 30: 334-344

[265] Xu Y, Qi J, Sun W, Zhong W, Wu H. Therapeutic effects of zoledronic acid-loaded hyaluronic acid/polyethylene glycol/nano-hydroxyapatite nanoparticles on osteosarcoma. Front. Bioeng. Biotechnol., 2022, 10: 897641

[266] Raghubir M, Rahman CN, Fang J, Matsui H, Mahajan SS. Osteosarcoma growth suppression by riluzole delivery via iron oxide nanocage in nude mice. Oncol. Rep., 2020, 43: 169-176

[267] Chen X et al. EDTA-modified 17beta-estradiol-laden upconversion nanocomposite for bone-targeted hormone replacement therapy for osteoporosis. Theranostics, 2020, 10: 3281-3292

[268] Hosny KM et al. Physically optimized nano-lipid carriers augment raloxifene and vitamin D oral bioavailability in healthy humans for management of osteoporosis. J. Pharm. Sci., 2020, 109: 2145-2155

[269] Tao S., et al H. A novel biocompatible, simvastatin-loaded, bone-targeting lipid nanocarrier for treating osteoporosis more effectively. RSC Adv. 10, 26699–26700 (2020).

[270] Cui Y et al. D. A bone-targeted engineered exosome platform delivering siRNA to treat osteoporosis. Bioact. Mater., 2021, 10: 207-221

[271] Marycz K et al. Nanohydroxyapatite (nHAp) doped with iron oxide nanoparticles (IO), miR-21 and miR-124 under magnetic field conditions modulates osteoblast viability, reduces inflammation and inhibits the growth of osteoclast—a novel concept for osteoporosis treatment: part 1. Int. J. Nanomed., 2021, 16: 3429-3456

[272] Kotak DJ, Devarajan PV. Bone targeted delivery of salmon calcitonin hydroxyapatite nanoparticles for sublingual osteoporosis therapy (SLOT). Nanomed. Nanotechnol. Biol. Med., 2020, 24: 102153

[273] Xi Y et al. Alendronate modified mPEG-PLGA nano-micelle drug delivery system loaded with astragaloside has anti-osteoporotic effect in rats. Drug Deliv., 2022, 29: 2386-2402

[274] Zhang C et al. Nanoparticles functionalized with stem cell secretome and CXCR4-overexpressing endothelial membrane for targeted osteoporosis therapy. J. Nanobiotechnol., 2022, 20

[275] Gaihre B, Lecka-Czernik B, Jayasuriya AC. Injectable nanosilica-chitosan microparticles for bone regeneration applications. J. Biomater. Appl., 2018, 32: 813-825

[276] Sun JL et al. Intrafibrillar silicified collagen scaffold promotes in-situ bone regeneration by activating the monocyte p38 signaling pathway. Acta Biomater., 2018, 67: 354-365

[277] Liao F et al. Gadolinium-doped mesoporous calcium silicate/chitosan scaffolds enhanced bone regeneration ability. Mater. Sci. Eng. C. Mater. Biol. Appl., 2019, 104

[278] Xue X., et al. Rational design of multifunctional cus nanoparticle-peg composite soft hydrogel-coated 3d hard polycaprolactone scaffolds for efficient bone regeneration. Adv. Funct. Mater. 32, 2202470 (2022).

[279] Basha G et al. Lipid nanoparticle-mediated silencing of osteogenic suppressor GNAS leads to osteogenic differentiation of mesenchymal stem cells in vivo. Mol. Ther., 2022, 30: 3034-3051

[280] Sun, R. et al. Highly porous amorphous calcium phosphate for drug delivery and bio-medical applications. Nanomaterials 10, 20 (2019).

[281] Sokolova V et al. Synthesis and characterization of PLGA/HAP scaffolds with DNA-functionalised calcium phosphate nanoparticles for bone tissue engineering. J. Mater. Sci. Mater. Med., 2020, 31: 102

[282] Liang Q et al. Development of tetracycline-modified nanoparticles for bone-targeted delivery of anti-tubercular drug. Front. Bioeng. Biotechnol., 2023, 11

[283] Salama AH, Abdelkhalek AA, Elkasabgy NA. Etoricoxib-loaded bio-adhesive hybridized polylactic acid-based nanoparticles as an intra-articular injection for the treatment of osteoarthritis. Int J. Pharm., 2020, 578: 119081

[284] Abdulrehman T et al. Boron doped silver-copper alloy nanoparticle targeting intracellular S. aureus in bone cells. PLoS One, 2020, 15: e0231276

[285] Peng KT et al. Treatment of osteomyelitis with teicoplanin-encapsulated biodegradable thermosensitive hydrogel nanoparticles. Biomaterials, 2010, 31: 5227-5236

[286] Kim T-J, Sun J, Lu S, Qi Y-X, Wang Y. Prolonged mechanical stretch initiates intracellular calcium oscillations in human mesenchymal stem cells. PLoS One, 2014, 9: e109378

Funding

National Natural Science Foundation of China (National Science Foundation of China)(22305117)